Postdoctoral Researcher in Computational Imaging and Machine Learning
Center for Computational Imaging and Personalized Diagnostics at Case Western Reserve University, Cleveland, OH, United States
The job you tried to view is no longer active on the site.
LATEST JOB POSTINGS
E-Mail
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell therapy - a type of immunotherapy - that killed pancreatic cancer cells in a pre-clinical model.
CAR T cell therapy is an immunotherapy that has shown great promise for the treatment of some blood cancers; however, the treatment of solid tumours using this therapy has proved very difficult. One barrier to success is toxicity in tissues other than the cancer because most of the proteins currently used to target CAR T cells to pancreatic cancer cells and other solid tumours are present in low levels on other normal tissues, leading to toxic side effects.
Share this article
KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ Researchers at Kanazawa University report in
Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however.
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly used for treating patients with NSCLC. It addresses a gene rearrangement known as ALK that occurs in 3 to 5% of NSCLC patients (alectinib belongs to a class of drugs called ALK tyrosine kinase inhibitors). It has been unclear, however, whether there is a correlation between the use of alectinib and the poore
A number of studies have shown that coffee helps to protect against breast cancer and new work led by Lund University has found that it also inhibits the growth of tumors and reduces risk of recurrence in women who have been treated with the drug tamoxifen.
In the cell study, the researchers looked more closely at two substances that usually occur in the coffee drunk in Sweden – caffeine and caffeic acid - and is a follow-up of the results the researchers obtained two years ago.
“Now, unlike in the previous study, we have combined information about the patients’ lifestyle and clinical data from 1,090 breast cancer patients with studies on breast cancer cells. The study shows that among the over 500 women treated with tamoxifen, those who had drunk at least two cups of coffee a day had only half the risk of recurrence of those who drank less coffee or none at all,” explain Lund researchers Ann Rosendahl and Helena Jernström, who obtained the results in collaboration with